The pharmaceutical brand was central to the vaccine effort in 2021 and registered a change in score of a whopping +12.5 points—nearly three times that of the next best improver. Several factors will make Pfizer’s brand health and momentum worth watching over the next year, especially with the rollout of the company’s COVID-19 vaccine booster in a time of growing concern for new strains of the virus.

Pharmaceutical companies are also vulnerable. Cybercriminals have targeted pharma and biotech firms to gain access to COVID-19 research and vaccine development data, according to Reposify’s 2021 report titled “Pharmaceutical Industry: The State of the External Attack Surface.” Some 92% of pharmaceutical companies had at least one exposed database with potential data leakage, the report noted.

What opportunities is the technology creating for hospitals, healthcare payers, and pharmaceutical companies? WHAT’S IN THIS REPORT? This report presents our user forecast for remote patient monitoring (RPM) through 2025, key trends driving adoption, and implications for the rapidly growing market.

Healthcare and pharma: Includes pharmaceutical products, facilities, services, researchers, drug manufacturers and marketers, doctors, hospitals, and biological products, as well as establishments providing healthcare services and social assistance for individuals; also includes health insurance.

Pharmaceutical Companies. Pharma companies are utilizing AI to accelerate the time-consuming—and expensive—drug discovery process. Traditionally, it takes pharmaceutical companies an average of 10 years and $3 billion to bring a drug to market.

Healthcare and pharma: Includes pharmaceutical products, facilities, services, researchers, drug manufacturers and marketers, doctors, hospitals, and biological products, as well as establishments providing healthcare services and social assistance for individuals; also includes health insurance.

Where it’s headed next: For one, the nimble startup snapped up biosensor maker Biovotion last year—and this April, it acquired Gaido Health from Takeda pharmaceuticals to wade into the oncology space. It also just bagged $100 million in Series C funding this September to expand its portfolio of offerings, which it could use to broaden its presence in Asian markets.

The $780 billion pharmaceuticals market is attracting tech firms that have been digging into segments across the healthcare continuum: Alphabet boasts its own life sciences arm, Verily, which is involved in projects—like its Project Baseline—that are amassing troves of data that could eventually help make care and treatments more precise and effective.

For example, last November, Janssen Pharmaceuticals teamed up with DTx provider Koa Health to research the effectiveness of deploying mental health DTx for major depressive disorder. And Boehringer Ingelheim inked a $500 million deal with DTx vendor Click Therapeutics to develop and commercialize a digital treatment for schizophrenic patients.